The scientific concept of probiotics has been widely accepted throughout the last decades; consequently, its industrial production and commercialization have been increased. This is only the beginning since a recent global probiotic market analysis estimated an annual growth, boosted mainly by a rising request from the Asian and European consumer in the next 5 years. So the pharmaceutical industry needs to develop new dosage forms containing probiotic microorganisms in order to offer consumers a variety of products. Different kinds of matrix tablets with Lactobacillus coryniformis CECT 5711 were designed to protect this strain from the technological process and harsh gastrointestinal conditions up until their arrival in the gut, as well as environmental conditions during their storage. With this aim, various retarding polymers were combined so as to get controlled release tablets. All formulations were evaluated in terms of technological processability, bacterial viability and stability. Finally, an optimal formulation with Methocel ® K-15 M EP, Eudragit L-100 and alginate sodium, which contain Lactobacillus coryniformis CECT 5711, was selected due to the fact that it assured an excellent survival of the microorganisms after their exposition to all conditions mentioned above, besides it will be able to improve human's health.
Introduction


The concept of probiotic was probably firstly introduced by the Russian Nobel laureate Elie Metchnikoff in 1907 (The Prolongation of Life: Optimistic Studies), he supported the idea that this kind of microbes were beneficial to human gastrointestinal tract [1] . The WHO (World Health Organization) and the Food and Agriculture Organization of the United Nations have defined probiotics as "live microorganism, which, when administered in adequate amounts, confer a health benefit on the host". This adequate amount varies from country to country; however, generally a probiotic product should contain more than 10 6~1 0 8 CFU/g or > 10 8~1 0 10 CFU (colony forming units)/dosage of viable cells [2] . Commercially, the most commonly used bacterial probiotics are Lactobacillus, Bifidobacteria, non-pathogenic E. coli Nissle 1917 and Saccharomyces boulardii. Increasing market interest in
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from an artisanal cheese elaborated from goat's milk by Biosearch Life; it was selected because of its broad antimicrobial activity within other probiotics properties like a high cellular adhesion and a 50% of survival in stomach [29] . Furthermore, this strain is well tolerated [30] and exerts a beneficial effect in the bowel function of healthy adult [31] . Studies are in progress to elucidate the effects of this strain on immunological parameters of healthy adult host [31, 32] .
The main problem associated with the administration of probiotic microorganisms is to maintain the survival of them along the gastrointestinal tract and storage conditions; therefore, there is a need for formulations which could protect the bacteria from the stomach acid and bile effects. It seems hard to judge whether probiotic food or supplements act more efficiently in exerting the claimed health effects. To our knowledge, only one study has compared the survivability of probiotic bacteria in food versus supplements. The results showed that the capsules used as supplement did not protect lactobacilli strain until the end of the gastrointestinal tract but the health effectiveness was not investigated and compared. Different forms of probiotic supplements are available in the market including pills, capsules, tablets, gelcaps, liquids and powders. In the pharmaceutical field, acid labile drugs are formulated mainly in tablets, which are able to ensure a higher protection and deliver the active substances into the intestinal tract. In addition, tablets have advantages over other dosage forms; these are ease of administration, accurate dosage, good patient acceptance and suitability for large-scale production [33, 34] . Based on this knowledge, we investigated whether it is possible to design a probiotic tablet supplement, which protects them from degradation at low pH and lets the delivery of the viable probiotics into the colon carrying out the beneficial effects. In this sense, we employ different polymers according to our objective; these polymers are for example hydroxypropyl methylcellulose (Methocel ® K-15 M EP) [35] [36] [37] [38] [39] [40] [41] and sodium alginate [42, 43] , which form hydrophilic matrix tablets in contact with aqueous media. Bacteria released from this kind of tablets are controlled by the formation of a hydrated viscous layer around the tablet, after ingestion of the dosage form. The surface acts as a release barrier by opposing penetration of water into the tablet and the dissolution of the matrix. The release of the microorganisms could be by diffusion through the gel layer or by erosion [44] [45] [46] [47] [48] , in this case, the release of the probiotic bacteria is by diffusion. The cellulose acetate phthalate provides lipophilic matrix tablets with an erosion process, which allows the probiotic release. Other polymers are Eudragit ® L-100, a metacrylic acid-ethhylacrylate copolymer [49, 50] and ethylcellulose, which is water-insoluble, both form inert matrix and its combination were investigated to overcome the problems of colonic delivery systems, such as a too short gastric resistance and premature release [50] .
In the present study, we intend to develop different matrix tablets with Lactobacillus coryniformis CECT 5711, a probiotic strain, which can achieve an optimal survival of bacteria after technological process, gastrointestinal tract until colon and storage conditions with the possibility of being marketed. Lastly, the current probiotic interest from consumers, scientists, and healthcare workers will only increase as more and better information is becoming available [51] . 
Materials and Methods
Materials
Methods
Tablets Preparation
Tablet processing took place by direct compression using a single punch manual tablet press (SPECAC SC-15011, Spain) connected to a pressure gauge. An exact amount of powder mixture containing Lactobacillus coryniformis CECT 5711 and different polymers in each case was poured into a 10 mm diameter die under a certain force ranging from 5 to 25 kN and several compression times. Tablets with plane surface were formed. The polymers were used in order to achieve a controlled release. Besides of polymers, tablets also contain a suitable amount of magnesium stearate as lubricant and talcum as antiadherant (0.1% and 0.9%, w/w, respectively). Tablets formulations designed in this study are summarized in Table 1 [52, 53] . Disintegration of tablets was examined by means of a disintegration apparatus (Erweka, Germany) and they were placed separately in the test chamber and then immersed in HCL 37% for 1 h and then in phosphate buffer solution PBS pH 6.8 for 24 h at 37 °C; the disintegration test ends when in each test chamber there is a soft residue of the tablets and it is completely impregnated and never is a non impregnated core [52] [53] [54] .
Tablets' mechanical strength was determined by using an Erweka TBH 20 (Germany) tester and the tensile strength (σ) was calculated by the following equation, where P is the measured crushing force (N), D is diameter and t is the thickness of the tablets [55] : "-": Formulation does not contain the polymer.
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Tablets' friability was measured by using a friabilator (Erweka GmbH, Germany) and mass uniformity test was realized with a precision balance (A&D Europe GmbH, Germany).
In Vitro Determination of Cell Release
Dissolution test was arranged according to our type of tablets with the aim of evaluating the release speed of probiotic microorganism and their gastric juice resistant by using the USP paddle method, with a paddle speed of 100 revolutions per minute (rpm) at 37 °C. Tablets were transferred into 600 mL of 0.04 N HCL acid (pH 1.7) during 2 h and then in PBS pH 6.8 for 4 h. At the end of the assay, the medium was removed and the viable cells inside tablets were determined. The test was realized in triplicate.
Viability of Cells Inside the Tablets: Microbiological Cultures
Each tablet was broken and dispersed in 50 mL of PBS pH 7. Tablets should be shaken during 1 h in an orbital shaker. After this time, a serial dilution of the suspension was made until a suitable cell density. Cell suspension was then spread onto MRS agar plates. These plates were incubated at 37 °C for 48 h. This procedure was carried out in duplicates. Colonies of bacteria were counted and converted to logCFU (colony forming units). The survival of probiotic cells was studied.
Stability of Probiotic Tablets
So as to perform stability testing, tablets were kept in hermetic containers at 4 °C, 25 °C and RT (room temperature) for one year. The stability of bacterial cells in these tablets throughout the storage period was investigated. The method used to determine cell viability was the plating procedure described above.
Results and Discussion
Bacterial Viability after Tableting
With the aim of selecting the best formulations, the effects of compression force and polymers on probiotic viability, as well as the stability of probiotic tablets during the storage at different temperatures, were studied.
A screening of compression force was carried out with several tablets that contained probiotic cells (Table 2 ). The assay was carried out in triplicate with all formulations. On account of the results that we had obtained (Table 2 ), 15 kN of compression force was selected as the optimal since all tablets have similar technological properties and adequate viability. We prepared our tablets with 0.1 g of this lyophilized, so the theoretical viability inside the tablets should be 1  10 10 CFU/tablet. As we can see in Table 3 , the viability inside tablets after applying 15 kN of compression force ranged from 2  10 9 to 6  10 9 CFU. The lethal effect of compression may be attributable to shearing forces caused by interparticules movement and pore size reduction within the matrix, leading to mechanical damage and death of the cells [56] . Some authors recommend a probiotic dosage of 5 billion CFU for at least 5 days in order to improve huma's health [57] .
Furthermore, Lara-Villoslada et al. [30] reported that a 
Probiotic Bacteria Survival inside Tablets in Gastric Juice
In order to provide beneficial health effects for the host, probiotic bacteria must survive through the gastrointestinal tract, tolerating acid and then adhere to and colonize the intestinal epithelium [58] . Firstly, probiotic bacteria resistance in acid was studied with the aim of selecting those formulations with an optimal viability after their immersion for 2 h in acid (HCl 0.04 N). Table 3 shows cells viability of each formulation just after tableting and after their exposure to gastric conditions.
If we compare all formulations, viability after their exposure to gastric conditions was reduced by 1logCFU in most of them. However, Formulations 4 and 5 were more affected by acid and their decrease in viability was 2logCFU. According to Stadler and Viernstein [52] , the decrease of 1log unit after 2 h of contact with acidic medium was a good achievement. As it is shown in Table 3 [50] , who claims that the addition of ethylcellulose to the enteric Eudragit L decreases the release of water-soluble drugs at low pH; surprisingly, the addition of only 2.5% ethylcellulose prolonged the gastric resistance beyond 18 h. Increasing the ethylcellulose amount decreased the weight increase ese formulatio after the as dosage [2] . P y of the rema philized bacte surface wit n [59] . 
In Vitro Dete
The low pH in detrimenta stomach. Th 2.5 to 3.5, bu rates of gastr food digesti ingested pro small intes exposed to between pH ability are e efficacy pro consider th interpretatio concentratio Table 5 and 
Stability of Probiotic Tablet
The stability of one of the optimized formulations had been tested (Formulation 14) ( Table 6 and Fig. 6 ). This formulation was selected in accordance with Values are mean (n = 3)  SD (standard deviation). 
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Eudragit L-100 and Methocel ® K-15 combination. As we have seen in Table 5 , Eudragit L-100 has a great influence in probiotic protection, so Formulations 10 and 14 have the best acid resistance. However, Formulation 10 was refused because of its higher amount of sodium alginate since in a previous work we notify that pH of the medium may influence negatively the rheology of alginate gel [64] , we can see this damage in Fig. 1 . All in all, we studied the viability of Formulation 14 during 365 days; tablets were stored at different conditions of temperature (RT, 4 °C, 25 °C). In a previous reported work, we had a decrease in viability after 180 days [64] , so the aim in this study was to enhance and improve the stability of our tablets.
As we can see in Table 6 , the viability inside our tablets did not change throughout the study (10 9 UFC/tablet) at the different temperatures. Owing to the results, we could confirm that the initial shock caused by the pressure had no effect on the remaining bacteria and did not make them more sensitive in storage conditions, thus the effect of both time and compression pressure on bacterial viability are independent [59] . Probiotics need to tolerate processing and storage conditions in order to be viable in a commercial product at the end of its shelf-life (> 10 6 CFU/g) [65] .
Conclusions
Probiotics have a brilliant future; applications will be both in the food domain and in very specific disease situations, where they can play a truly therapeutic role. Success, however, will depend on a number of, mostly interlinked, conditions. The need arises to develop new formulations with them, which overcome problems associated with these microorganisms and assure their survival at the end of their shelf life in a suitable number of viable cells. Among the different matrix tablet formulations that were developed with Lactobacillus coryniformis CECT 5711, the combination of alginate sodium (25 mg), Methocel ® K-15 M EP (100 mg) and Eudragit ® L-100 (75 mg) had the best technological and viability assays results, as well as good biocompatibility and biodegradability polymers properties. The viability inside tablets after compression was 5  10 9 CFU/tablet, so tablets offer an amazing protection to probiotic cells during this process. Furthermore, once tablets had passed stomach acid medium, the viability decreased in 1logCFU (5  10 8 CFU/tablet) but it is already an effective dosage. Thus, this tablet dosage form is certainly an interesting way to improve probiotic resistance in harsh conditions and allows the strain to reach the therapeutic target in adequate amounts. Stability study confirmed a tablet viability of 10 9 during 365 days at different temperatures reaching our goals. If we consider all of these properties, the formulation proposed to Lactobacillus coryniformis CECT 5711 would be optimal for being marketed.
While it is essential to refuse all false claims and prevent misleading information being distributed to the public, the possibility to communicate positively proven health benefits is necessary to promote the use of probiotics in a number of conditions that have the potential to reduce substantially the health care cost for society.
